Oral thin film drug is a promising drug
delivery dosage form, which delivers drugs by adhering to the oral
mucosa. Oral thin film drugs are a strip of multilayered or single
layered, non-muco-adhesive or muco-adhesive, thin polymeric films that
are intended to deliver active therapeutic moieties either systemically
or locally in oral cavity through palatal, buccal, or sublingual
absorption. These offer several advantages such as bypassing the hepatic
first pass effect, fast onset of action, and ease of transportation.
These films offer rapid absorption and high bioavailability for the
drugs. Types of oral thin film drugs are fast disintegrating buccal
film, melt away film, and non-disintegrating buccal film. An ultra-thin
film quickly dissolves on the buccal cavity or tongue or on the top of
the tongue. This is prepared using hydrophilic polymers that have fast
dissolving property.
Oral thin film drugs are kept on a
patient’s oral mucosal tissue or tongue, which gets wet by saliva and
quickly hydrates and adheres on the site of application. This
disintegrates within a few seconds to promote oromucosal absorption.
Increase in inclination toward non-invasive or minimally invasive
treatment drives demand for oral thin film drugs. These drugs offer high
therapeutic index with good physical properties such as faster
disintegration and dissolution. Moreover, the oral thin film drug
delivery system allows to bypass the first pass metabolism and ensures
higher bioavailability. Demand for oral thin film drugs has been
increasing across the world owing to technological advancements in these
products. These drugs have experienced significant market acceptance
due to high effectiveness and ease of application. However, high cost of
treatment can impact market adoption of these drugs.
The global oral thin film drugs market
can be segmented based on product type, disease type, distribution
channel, and region. In terms of product type, the market can be divided
into fully dissolving dental or buccal film, and sublingual film. Based
on disease type, the global oral thin film drugs market can be
classified into schizophrenia, migraine, opioid dependence, nausea &
vomiting, and others. In terms of distribution channel, the market can
be categorized into online pharmacies, retail pharmacies, and hospital
pharmacies.
Geographically, the global oral thin film
drugs market can be segmented into Latin America, Europe, North
America, Middle East & Africa, and Asia Pacific. North America held
large market share in 2016 owing to high market acceptance of innovative
drug delivery systems and better therapeutic outcome of the oral dosage
form. Europe held the second largest market share due to strong product
pipeline, significant research activities, and high market adoption of
oral thin film drug delivery. The market in Asia Pacific is anticipated
to be driven during the forecast period by continuous introduction of
new technology. The global oral thin film drugs market in Middle East
& Africa and Latin America is expected to witness significant growth
during the forecast period due to major pharmaceutical players are
focusing their efforts toward providing services to the large and
growing populations in countries in the Middle East and developing
countries in Latin America.
Key players in the global oral thin film
drugs market include ZIM Laboratories Limited, Indivior plc, MonoSol Rx,
Sumitomo Dainippon Pharma Co., Ltd., IntelGenx Corp., and Pfizer, Inc.
No comments:
Post a Comment